---
provider: claude_code
model: claude-haiku-5-5, claude-opus-5-5
cached: false
start_time: '2026-10-26T13:21:07.589452'
end_time: '2026-10-26T13:24:01.236224'
duration_seconds: 173.65
template_file: templates/disease_pathophysiology_research.md
template_sha: "f452f0a9c7e3536175154b9683c45663f686f283"
template_variables:
  disease_name: Chitayat Syndrome
  mondo_id: MONDO:0014956
  category: Mendelian
  causal_genes: ERF
  omim_id: OMIM:617180
  synonyms: CHYTS; Chitayat syndrome; CHYTS
provider_config:
  timeout: 1800
  max_retries: 3
  parameters:
    allowed_domains: []
    claude_executable: claude
    skip_permissions: false
    allowed_tools:
    - WebSearch
    - WebFetch
    add_dirs: []
    timeout: 1800
    min_report_chars: 200
    extra_args: []
run_metadata:
  models_used:
  - claude-haiku-5-5
  - claude-opus-5-5
  web_search_requests: 3
  num_turns: 28
  total_cost_usd: 2.3940104999999994
  session_id: a41a936c-037a-41c6-8e94-02618586750e
  stop_reason: end_turn
  permission_denials: 3
  denied_tools:
  - Bash
  assistant_text_blocks: 3
fell_back: true
requested_provider: falcon
provider_attempts:
- provider: falcon
  succeeded: false
  error_type: ProviderNotConfiguredError
  remedy: the provider is not configured
  retryable: false
- provider: claude_code
  succeeded: true
citation_count: 4
reference_validation:
  total_references: 14
  verified: 14
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  relevance_assessed: 14
  on_topic: 10
  off_topic: 1
  off_topic_references:
  - PMID:17515308
  needs_review: true
  validator_version: 0.4.0
term_validation:
  total_terms: 31
  verified: 31
  not_found: 0
  obsolete: 0
  unverifiable: 0
  confabulation_rate: 0.0
  labels_checked: 12
  labels_matching: 6
  labels_mismatched: 2
  mislabelled_terms:
  - term_id: HP:0001363
    reported_labels:
    - excluded
    ontology_label: Craniosynostosis
  - term_id: NCIT:C15747
    reported_labels:
    - bind a more specific term only if found by lookup
    ontology_label: Supportive Care
  labels_variant: 4
  needs_review: true
  adapter: 'ols:'
  validator_version: 0.4.5
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Chitayat Syndrome
- **MONDO ID:** MONDO:0014956 (if available)
- **Causal gene(s):** ERF
- **OMIM:** OMIM:617180
- **Synonyms:** CHYTS; Chitayat syndrome; CHYTS
- **Category:** Mendelian

Many disease names are serial numbers ("... autosomal dominant 64", "... 26") that
do not say which gene the disease is about, and a similarly named disease with a
different gene is easy to research by mistake. Research the disease with the MONDO
ID and causal gene given above, and name its causal gene in your first paragraph.
If the name seems to point to a different gene or OMIM entry, follow the
identifiers above.

## Research Objectives

Please provide a comprehensive research report on **Chitayat Syndrome** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

Using Read instead.

I'm checking MONDO cross-references, then I'll write the report.

I've finished the lookups and am writing the report now.

# Chitayat Syndrome (MONDO:0014956; OMIM #617180): Research Report

**Causal gene: *ERF*** (ETS2 repressor factor; HGNC `hgnc:3444`; OMIM *611888; 19q13.2). Chitayat syndrome (CHYTS) is caused by a single recurrent heterozygous missense variant in *ERF*: NM_006494.2:c.266A>G, p.(Tyr89Cys), rs886041001. It changes a conserved residue in the ETS DNA-binding domain.

> **Read this before curating: four names and reports that can be confused with this disease**
> 1. **ERF-related craniosynostosis (CRS4, OMIM 600775).** Heterozygous loss-of-function *ERF* variants cause this. It is a separate disease, and no p.Tyr89Cys carrier has had craniosynostosis.
> 2. **ERF loss-of-function "Noonan-like" phenotype (2024)** and **MIDES syndrome (FSF-motif variants, 2025).** Both are separate *ERF* conditions.
> 3. **PMID:40840652 (Zhu et al. 2025)** calls its patient "Chitayat syndrome", but the variant is a frameshift, c.1201_1202del p.(Lys401Glufs*10). That exact variant recurs in the Noonan-like loss-of-function cohort (PMID:38824261), and the patient's features (short stature, facial dysmorphism, developmental delay) fit that phenotype better than CHYTS. **Do not use it as evidence for CHYTS.** At most, cite it in a note about the misattribution.
> 4. **Roifman–Chitayat syndrome** (PMID:29180244, *PIK3CD*/*KNSTRN*) and **"Chitayat syndrome revisited"** (PMID:17515308, distal contractures with intellectual disability) are both unrelated to *ERF* and to MONDO:0014956.

---

## 1. Disease information

**Overview.** CHYTS is an ultra-rare autosomal dominant malformation syndrome. Its features are:
- bilateral hyperphalangism of the index fingers, which leaves them short and ulnarly deviated;
- hallux valgus;
- mild facial dysmorphism;
- neonatal or infantile respiratory compromise, often from airway malacia (bronchomalacia).

Chitayat et al. first described it in 1993 in a French-Canadian boy (PMID:8418638). The molecular cause was found in 2017 (PMID:27738187).

**Identifiers**

| Source | ID |
|---|---|
| MONDO | MONDO:0014956 "Chitayat syndrome" |
| OMIM | 617180 |
| MedGen | 934646 |
| UMLS | C4310679 |
| Orphanet | Not found. MONDO lists no ORPHA xref and the local Orphanet cache has no hit. Check orpha.net directly. |
| ICD-10 / ICD-11 / MeSH | No disease-specific code found. It would fall under general codes for congenital malformation syndromes. |

The OLS query showed **MONDO has no textual definition** for this term.

**Synonyms:** CHYTS; "Hyperphalangism, facial anomalies, hallux valgus, and bronchomalacia" (the 1993 title).

**Evidence base:** individual case reports and small case series only. There are no registries and no EHR-derived data.

## 2. Etiology

- **Causal factor (genetic).** Heterozygous *ERF* c.266A>G p.(Tyr89Cys). Balasubramanian et al. (PMID:27738187) report: *"A recurrent, novel variant NM_006494.2:c.266A>G p.(Tyr89Cys) in ERF was identified in five affected individuals: de novo (patient 1, 2 and 3) and inherited from an affected father (patient 4 and 5)."*
- **Risk factors.** The only one is having an affected parent (50% risk to offspring). No environmental risk factors are known.
- **Protective factors and gene–environment interactions.** None reported.

## 3. Phenotypes

The HPO CURIEs below were checked against `cache/hp/terms.csv`. Terms marked † were not in the cache and must be looked up before binding.

| Phenotype | HPO | Frequency / notes | Key source |
|---|---|---|---|
| Hyperphalangism of index fingers (accessory phalanx) | Hyperphalangy† | Present in most cases but **not all**; absent in the Mexican case, which had hypoplastic phalanges instead | PMID:27738187; PMID:30569521 |
| Short index finger | HP:0009536 Short 2nd finger | Core feature | PMID:27738187; PMID:32592542 |
| Ulnar deviation of index finger | HP:0009464 Ulnar deviation of the 2nd finger | Core feature | PMID:32592542 |
| Hypoplastic or delta-shaped proximal phalanges | Delta phalanx† | Seen on radiographs | PMID:30728880 |
| Clinodactyly of the 4th and 5th fingers | HP:0004209 | Reported | PMID:30728880 |
| Hallux valgus | HP:0001822 | Core feature | PMID:27738187; PMID:30728880 |
| Respiratory distress (neonatal) | HP:0002643 / HP:0002098 | 14/15 (93.3%) in the 2025 literature review | PMID:40763971 |
| Bronchomalacia / tracheomalacia | HP:0002780 / HP:0002779 | Confirmed airway malacia in 7/15 (46.7%) | PMID:40763971; PMID:30728880 |
| Recurrent respiratory infections | HP:0002205 | 7/15 (46.7%) | PMID:40763971 |
| Interstitial lung changes (chILD: dilated alveoli, thickened septa on biopsy) | Need lookup | Single case report | PMID:41567031 |
| Developmental delay | HP:0001263 | 8/15 (53.3%) | PMID:40763971 |
| Growth delay | HP:0004322 (short stature) | 8/15 (53.3%) | PMID:40763971 |
| Feeding difficulties (secondary to tachypnoea) | HP:0011968 | Reported | PMID:30728880 |
| Hypertelorism | HP:0000316 | Common | PMID:30728880 (quoting PMID:27738187) |
| Large anterior fontanelle | Large anterior fontanel† | Common | PMID:30728880 |
| Prominent eyes | HP:0000520 Proptosis | Reported | PMID:30728880 |
| Depressed / flat nasal bridge | HP:0005280 | Common | PMID:30728880 |
| Anteverted nares | HP:0000463 | Reported | PMID:30728880 |
| Low posterior hairline; epicanthus | HP:0002162; HP:0000286 | Single case | PMID:30728880 |
| Low-set ears; hypotonia | HP:0000369; HP:0001252 | Single case | PMID:41567031 |
| Pectus carinatum | HP:0000768 | Single case | PMID:30569521 |
| Pierre-Robin / micrognathia | HP:0000201 / HP:0000347 | Some cases. Pierre Robin is a MeSH keyword of PMID:32592542; confirm in the full text | PMID:32592542 |
| Partial syndactyly | Need lookup | Original 1993 case | PMID:8418638 |
| **Craniosynostosis (absent)** | HP:0001363 (excluded) | Absent in all p.Tyr89Cys carriers | PMID:27738187 |

**Pulmonary variability.** Suter et al. (PMID:32592542) note the respiratory phenotype ranges widely: *"among them only one presenting with a history of assisted ventilation, and the remaining presenting with variable pulmonary phenotypes, including one individual without any obvious pulmonary manifestations."* They add that CHYTS can present as *"isolated skeletal malformations."*

**Onset:** congenital. Respiratory problems appear from birth or in the first hours of life.

**Quality of life:** no instrument-based data exist. The burden comes mainly from respiratory illness, including hospitalizations, home oxygen and tracheotomy.

## 4. Genetic and molecular information

- **Gene:** *ERF* (`hgnc:3444`), 4 exons. The protein has an N-terminal ETS DNA-binding domain, a central ERK-interaction region (FSF motif) and a C-terminal repressor domain (PMID:23354439).
- **Variant:** c.266A>G p.(Tyr89Cys), a missense change, germline, either de novo or inherited.
  - Caro-Contreras et al. (PMID:30569521): *"caused by a single missense pathogenic variant in the ERF gene."*
  - Li et al. (PMID:40763971) classified it **Pathogenic** using PM1, PM2_Supporting, PM6, PS1 and PP3.
- **Population frequency:** not verified here. Check gnomAD for rs886041001; it is expected to be absent.
- **Functional consequence:** unresolved. Suter et al. (PMID:32592542) say *"The pathomechanism of Chitayat syndrome is unknown."* What is known:
  - The phenotype differs from *ERF* haploinsufficiency (craniosynostosis or Noonan-like), which argues against simple loss of function. A qualitatively altered DNA-binding function, such as a neomorphic or dominant-negative effect, is a hypothesis only.
  - Dentici et al. (PMID:38824261): Tyr89 *"directly contributes to the intermolecular binding network stabilizing ERF interaction with DNA… The nonconservative substitution is expected to affect proper binding of ERF to DNA."*
  - In *C. elegans*, a substitution at the equivalent residue of LIN-1 impairs DNA binding and upregulates RAS–MAPK output.
- **Genotype–phenotype correlations across *ERF* disorders:**

| Variant class | Phenotype | Source |
|---|---|---|
| Truncating / loss of function | CRS4 craniosynostosis | PMID:23354439 |
| Truncating / loss of function | Noonan-like syndrome with or without craniosynostosis | PMID:38824261 |
| ETS-domain missense near Tyr89 (p.Arg65Gln, p.Arg86Cys) | CRS4 | PMID:23354439 |
| FSF-motif in-frame changes (ERK-binding disrupted, increased nuclear ERF) | MIDES | PMID:39668184 |
| p.Tyr89Cys | CHYTS | PMID:27738187 |

- **Modifier genes, epigenetics, chromosomal abnormalities:** none reported.

## 5. Environmental information

None applicable. There are no known environmental, lifestyle or infectious causes. Respiratory infections, including bronchiolitis and *Pseudomonas aeruginosa* pneumonia, are complications rather than causes (PMID:30728880; PMID:41567031).

## 6. Mechanism and pathophysiology

**Causal chain** (steps 3–5 are inferred, not demonstrated):

1. A germline heterozygous *ERF* c.266A>G **leads to** a p.Tyr89Cys substitution in the ETS DNA-binding domain (PMID:27738187).
2. The substitution **is predicted to alter** ERF–DNA contacts. The evidence is structural modelling and homology: AlphaFold modelling shows greater distance between the side chain and DNA (PMID:40763971), and Dentici et al. infer the effect from the LIN-1 equivalent (PMID:38824261). *No direct biochemical assay of Y89C has been published.*
3. Changed DNA binding **is hypothesized to perturb** ERF's normal job of repressing ETS/AP-1/RUNX-dependent transcription downstream of RAS–ERK1/2. The baseline biology comes from ChIP-seq: ERF binds distal elements containing RUNX and AP-1 motifs and antagonizes RUNX2 (PMID:23354439). For CHYTS specifically this is inferred.
4. **Branch A, limb development:** abnormal transcriptional regulation in limb mesenchyme or chondrogenic cells **results in** an accessory or delta-shaped phalanx in digit 2, giving a short, ulnarly deviated index finger, plus hallux valgus. The mechanism is undemonstrated.
5. **Branch B, airway development:** abnormal regulation in tracheobronchial cartilage or airway mesenchyme **results in** bronchomalacia or tracheomalacia, and in some cases interstitial or alveolar changes. This produces neonatal respiratory distress, recurrent infections and, rarely, death from pneumonia. Undemonstrated.
6. **Contrast with the other *ERF* disorders:** CHYTS has no craniosynostosis, whereas reduced ERF dosage causes it. This shows the Y89C effect is **not** equivalent to haploinsufficiency (PMID:27738187; PMID:23354439).

**Suggested ontology terms** (verify every CURIE with `runoak` before binding):

| Category | Suggestions |
|---|---|
| GO biological process | negative regulation of DNA-templated transcription; ERK1 and ERK2 cascade (or its regulation); skeletal system development; embryonic digit morphogenesis; cartilage development; lung development; regulation of osteoblast differentiation |
| GO molecular function | DNA-binding transcription repressor activity, RNA polymerase II-specific |
| CL cell types | chondrocyte; mesenchymal cell; osteoblast |
| GO cellular component | nucleus. ERF shuttles between nucleus and cytoplasm depending on ERK phosphorylation (PMID:38824261; PMID:39668184) |

**Molecular profiling, omics, single-cell studies:** none exist for CHYTS.

**Structural data:** ERF ETS domain–DNA crystal structures (dimer and Cys72-linked tetramer; PMID:33175491) could anchor modelling of Tyr89.

## 7. Anatomical structures affected

| Level | Structures (suggested UBERON terms) | Notes |
|---|---|---|
| Primary sites | manual digit 2 / index finger phalanges; hallux (pedal digit 1); bronchus and trachea; lung parenchyma (in one biopsy) | Hand findings are bilateral |
| Craniofacial | anterior fontanelle, orbit, nose; no suture fusion | |
| Body systems | musculoskeletal, respiratory; neurodevelopmental in about half of cases | |
| Tissue level | cartilage and bone (phalangeal); airway cartilage | |

## 8. Temporal development

- **Onset:** congenital, with respiratory symptoms from birth.
- **Respiratory course:** usually improves with age as the airways grow, but some infants need prolonged home oxygen (to 11 months in PMID:30728880) or tracheotomy.
- **Skeletal findings:** static.
- **Critical period:** the neonatal and infant period, which is the window of respiratory vulnerability.

## 9. Inheritance and population

- **Inheritance:** autosomal dominant (HP:0000006; verify).
  - de novo in 3 of the 5 original patients;
  - father-to-child transmission in one family (PMID:27738187).
- **Penetrance:** apparently complete.
- **Expressivity:** highly variable, especially for the lungs; one individual had isolated skeletal findings (PMID:32592542).
- **Anticipation:** none.
- **Germline mosaicism, founder effect, consanguinity:** none reported.
- **Prevalence:** unknown; better described as *cases in the literature*.
  - About 13 affected individuals from 9 families as of 2024 (PMID:38824261).
  - 15 genetically confirmed cases, including the index case, in the 2025 review (PMID:40763971).
  - Plus the 2026 Croatian case (PMID:41567031).
  - For a dismech `prevalence` record: `measure_type: CASES_IN_LITERATURE`, `prevalence_class: ULTRA_RARE`.
- **Geography and sex:** cases reported from Canada, UK, USA, Mexico, Germany/Denmark/Spain/Argentina (Suter series), China and Croatia. Both sexes are affected.

## 10. Diagnostics

- **Clinical suspicion:** shortened, ulnarly deviated index fingers with hallux valgus, especially together with neonatal respiratory distress.
- **Imaging:**
  - Hand and foot radiographs show an accessory or delta-shaped phalanx and hallux valgus (PMID:30728880).
  - Chest radiograph shows hyperinflation (PMID:41567031).
  - Bronchoscopy confirms malacia (PMID:30728880).
  - Lung biopsy in one case showed dilated alveoli and thickened septa (PMID:41567031).
- **Genetic testing:** targeted Sanger sequencing for c.266A>G, or exome sequencing (trio or proband-only), which is how all recent cases were found (PMID:27738187; PMID:40763971). Chromosomal microarray is not informative.
- **Differential diagnosis** (from PMID:30728880):

| Condition | Gene | Distinguishing features |
|---|---|---|
| Catel–Manzke syndrome | *TGDS* | Index-finger hyperphalangy plus Pierre Robin sequence |
| Temtamy preaxial brachydactyly–hyperphalangism | *CHSY1* | Hearing loss |
| ERF craniosynostosis (CRS4) | *ERF* (loss of function) | Craniosynostosis |
| Noonan-like *ERF* phenotype | *ERF* (loss of function) | Noonan-like facies, short stature |

- **Screening:** none at population level. Cascade testing of a parent is appropriate.

## 11. Outcome and prognosis

- **Mortality:** deaths reported in infancy.
  - One child died of severe pneumonia at 13 months (PMID:40763971).
  - One died at 1 year 5 months of *Pseudomonas aeruginosa* infection after tracheotomy (PMID:41567031).
- **Overall:** survivors generally improve respiratorily. About half have developmental or growth delay (PMID:40763971).
- **Prognostic factor:** severity of airway or lung disease. Li et al.: *"Airway management and early intervention of developmental delay are important for improving the prognosis."*
- **Formal survival data:** none.

## 12. Treatment

All treatment is supportive. There are no disease-specific drugs, trials or gene therapies.

| Intervention | Suggested NCIT (verify) | Source |
|---|---|---|
| Oxygen therapy / respiratory support, mechanical ventilation | Supportive Care, NCIT:C15747 (bind a more specific term only if found by lookup) | PMID:30728880; PMID:41567031 |
| Surfactant administration | Pharmacotherapy, NCIT:C15986, plus `therapeutic_agent` | PMID:41567031 |
| Tracheotomy | Surgical Procedure, NCIT:C15329 | PMID:41567031 |
| Nasogastric or nutritional support | Nutritional Support, NCIT:C15433 | PMID:30728880; PMID:40763971 |
| Rehabilitation for developmental delay | Rehabilitation, NCIT:C15315 | PMID:40763971 |

- **Growth hormone:** reported only in the misattributed frameshift case (PMID:40840652). Do not use it for CHYTS.
- **MEK inhibition:** partially rescues craniosynostosis in *Erf*-deficient mice (cited in PMID:38824261). It is irrelevant and untested for CHYTS.

## 13. Prevention

- **Primary prevention:** none.
- **Genetic counselling:** 50% recurrence risk when a parent carries the variant; low but non-zero risk after a de novo case because of possible gonadal mosaicism.
- **Reproductive options:** prenatal or preimplantation testing is possible once the familial variant is known.
- **Tertiary prevention:** airway surveillance; prompt treatment of respiratory infections; infection prophylaxis (immunizations such as RSV prophylaxis are reasonable but not studied in CHYTS).

## 14. Other species

No naturally occurring animal disease is known; the OMIA search was not performed. Orthologs are mouse *Erf* and *C. elegans* *lin-1*. The *lin-1* ortholog is relevant because the residue equivalent to Tyr89 is functionally important there (PMID:38824261).

## 15. Model organisms

- **No CHYTS-specific (Y89C) model exists.**
- **Related *Erf* mouse models** (PMID:23354439, model organism evidence):
  - *Erf*⁺/⁻ mice are normal.
  - *Erf*⁻/⁻ mice die by E10.5 from placental defects.
  - Hypomorphic *Erf*^loxP/− mice (about 30% expression) get postnatal multisuture craniosynostosis.
  - These model haploinsufficiency (CRS4), **not** CHYTS. They show no limb or airway defect: *"No other specific skeletal abnormalities were evident."*
- **Research gap:** a knock-in *Erf* p.Y89C mouse, and DNA-binding assays such as EMSA or ChIP comparing Y89C with wild type, would test the hypothesis that the variant acts by a mechanism other than loss of function.

---

## Key evidence (cached in `references_cache/`)

| PMID | Type | Use |
|---|---|---|
| 8418638 | Case report, 1993 | Original description |
| 27738187 | Case series (5 patients), 2017 | Gene discovery; de novo and inherited cases; no craniosynostosis |
| 30569521 | Case report | 6th patient; pectus carinatum; no hyperphalangism; AD |
| 30728880 | Case report, full text | Radiology; bronchomalacia confirmed on bronchoscopy; differential diagnosis |
| 32592542 | Case series (6 patients) | Variable pulmonary phenotype; pathomechanism unknown |
| 38824261 | Cohort, full text | Contrasts *ERF* loss of function with CHYTS; Tyr89–DNA contact; count of 13 CHYTS patients |
| 39668184 | Cohort | MIDES; *ERF* allelic spectrum |
| 40763971 | Case report and literature review | Frequencies across 15 cases; death at 13 months; management |
| 41567031 | Case report, 2026 | Preterm infant; chILD on biopsy; tracheotomy; death at 17 months |
| 23354439 | Human genetics and mouse study | ERF biology; CRS4; *Erf* mouse models |
| 40840652 | Case report | ⚠️ Frameshift variant mislabelled as CHYTS; exclude as evidence |
| 33175491 | Structural study, not cached | ERF–DNA crystal structures |

Sources consulted beyond the local cache: [MONDO via OLS](https://www.ebi.ac.uk/ols4/ontologies/mondo/classes?obo_id=MONDO:0014956), PubMed E-utilities (search for "chitayat syndrome"[tiab], 12 hits), [JMG 2017 article](https://jmg.bmj.com/content/54/3/157), [Structural Insight into the DNA Binding Function of ERF](https://scholars.uthscsa.edu/en/publications/structural-insight-into-the-dna-binding-function-of-transcription/), [PubMed 39668184](https://pubmed.ncbi.nlm.nih.gov/39668184/).

**Not verified here:** an Orphanet code, gnomAD frequency, ClinVar classification of rs886041001, and the CURIEs marked † or "verify". Whether Pierre Robin is reported in PMID:32592542 is also unconfirmed; it appears only as a MeSH keyword.

## Reference Validation

Checked with `linkml-reference-validator` 0.4.0.

| Outcome | Count |
| --- | --- |
| References checked | 14 |
| Resolved | 14 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 14 |
| On topic | 10 |
| Off topic | 1 |

### References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

- `PMID:17515308` (1 mention) - Distal joint contractures, mental retardation, characteristic face and growth retardation: Chitayat syndrome revisited.
  - shared terms: syndrome

Weighed against this report's own most characteristic terms: `erf`, `chyt`, `respiratory`, `craniosynostosis`, `airway`, `variant`, `gene`, `index`, `lung`, `syndrome`, `phenotype`, `finger`, `function`, `tyr89cy`, `hallux`, `crs4`, `infection`, `genetic`, `neonatal`, `novo`.

All extracted references resolved successfully.
Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 31 |
| Resolved | 31 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 0 |
| Unverifiable | 0 |
| Terms whose name was checked | 12 |
| Terms named correctly | 6 |
| Terms named as a **different** term | 2 |
| Terms whose name is worth a second look | 4 |

### Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

- `HP:0001363` (1 mention) - the report calls it "excluded"; HP calls it **Craniosynostosis**
- `NCIT:C15747` (1 mention) - the report calls it "bind a more specific term only if found by lookup"; NCIT calls it **Supportive Care**

### Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a *related* synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

- `HP:0004209` (1 mention) - the report calls it "Clinodactyly of the 4th and 5th fingers"; HP calls it **Clinodactyly of the 5th finger**
- `HP:0001263` (1 mention) - the report calls it "Developmental delay"; HP calls it **Global developmental delay**, and lists "Developmental delay" among its other names
- `HP:0011968` (1 mention) - the report calls it "Feeding difficulties (secondary to tachypnoea)"; HP calls it **Feeding difficulties**
- `HP:0005280` (1 mention) - the report calls it "Depressed / flat nasal bridge"; HP calls it **Depressed nasal bridge**